Cargando…
Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
INTRODUCTION: On October 12, 2021, the FDA issued its first marketing granted orders for Vuse, the e-cigarette product by R.J. Reynolds Vapor Company. The public perceptions and reactions to the FDA’s Vuse authorization are prevalent on social media platforms such as Twitter/X. We aim to understand...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654997/ https://www.ncbi.nlm.nih.gov/pubmed/38026290 http://dx.doi.org/10.3389/fpubh.2023.1280658 |
_version_ | 1785136731017707520 |
---|---|
author | Lee, Sarah Xie, Zidian Xu, Emily Shao, Yihan Ossip, Deborah J. Li, Dongmei |
author_facet | Lee, Sarah Xie, Zidian Xu, Emily Shao, Yihan Ossip, Deborah J. Li, Dongmei |
author_sort | Lee, Sarah |
collection | PubMed |
description | INTRODUCTION: On October 12, 2021, the FDA issued its first marketing granted orders for Vuse, the e-cigarette product by R.J. Reynolds Vapor Company. The public perceptions and reactions to the FDA’s Vuse authorization are prevalent on social media platforms such as Twitter/X. We aim to understand public perceptions of the FDA’s Vuse authorization in the US using Twitter/X data. METHODS: Through the Twitter/X streaming API (Application Programming Interface), 3,852 tweets between October 12, 2021, and October 23, 2021, were downloaded using the keyword of Vuse. With the elimination of retweets, irrelevant tweets, and tweets from other countries, the final dataset consisted of 523 relevant tweets from the US. Based on their attitudes toward the FDA authorization on Vuse, these tweets were coded into three major categories: positive, negative, and neutral. These tweets were further manually classified into different categories based on their contents. RESULTS: There was a large peak on Twitter/X mentioning FDA’s Vuse authorization on October 13, 2021, just after the authorization was announced. Of the 523 US tweets related to FDA’s Vuse authorization, 6.12% (n=32) were positive, 26.77% (n=140) were negative, and 67.11% (n=351) were neutral. In positive tweets, the dominant subcategory was Cessation Claims (n=18, 56.25%). In negative tweets, the topics Health Risk (n=43, 30.71%), Criticize Authorization (n=42, 30.00%), and Big Tobacco (n=40, 38.57%) were the major topics. News (n=271, 77.21%) was the most prevalent topic among neutral tweets. In addition, tweets with a positive attitude tend to have more likes. DISCUSSION: Public perceptions and discussions on Twitter/X regarding the FDA’s Vuse authorization in the US showed that Twitter/X users were more likely to show a negative than a positive attitude with a major concern about health risks. |
format | Online Article Text |
id | pubmed-10654997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106549972023-11-03 Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X Lee, Sarah Xie, Zidian Xu, Emily Shao, Yihan Ossip, Deborah J. Li, Dongmei Front Public Health Public Health INTRODUCTION: On October 12, 2021, the FDA issued its first marketing granted orders for Vuse, the e-cigarette product by R.J. Reynolds Vapor Company. The public perceptions and reactions to the FDA’s Vuse authorization are prevalent on social media platforms such as Twitter/X. We aim to understand public perceptions of the FDA’s Vuse authorization in the US using Twitter/X data. METHODS: Through the Twitter/X streaming API (Application Programming Interface), 3,852 tweets between October 12, 2021, and October 23, 2021, were downloaded using the keyword of Vuse. With the elimination of retweets, irrelevant tweets, and tweets from other countries, the final dataset consisted of 523 relevant tweets from the US. Based on their attitudes toward the FDA authorization on Vuse, these tweets were coded into three major categories: positive, negative, and neutral. These tweets were further manually classified into different categories based on their contents. RESULTS: There was a large peak on Twitter/X mentioning FDA’s Vuse authorization on October 13, 2021, just after the authorization was announced. Of the 523 US tweets related to FDA’s Vuse authorization, 6.12% (n=32) were positive, 26.77% (n=140) were negative, and 67.11% (n=351) were neutral. In positive tweets, the dominant subcategory was Cessation Claims (n=18, 56.25%). In negative tweets, the topics Health Risk (n=43, 30.71%), Criticize Authorization (n=42, 30.00%), and Big Tobacco (n=40, 38.57%) were the major topics. News (n=271, 77.21%) was the most prevalent topic among neutral tweets. In addition, tweets with a positive attitude tend to have more likes. DISCUSSION: Public perceptions and discussions on Twitter/X regarding the FDA’s Vuse authorization in the US showed that Twitter/X users were more likely to show a negative than a positive attitude with a major concern about health risks. Frontiers Media S.A. 2023-11-03 /pmc/articles/PMC10654997/ /pubmed/38026290 http://dx.doi.org/10.3389/fpubh.2023.1280658 Text en Copyright © 2023 Lee, Xie, Xu, Shao, Ossip and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Lee, Sarah Xie, Zidian Xu, Emily Shao, Yihan Ossip, Deborah J. Li, Dongmei Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X |
title | Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X |
title_full | Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X |
title_fullStr | Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X |
title_full_unstemmed | Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X |
title_short | Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X |
title_sort | public perceptions of the fda’s marketing authorization of vuse on twitter/x |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654997/ https://www.ncbi.nlm.nih.gov/pubmed/38026290 http://dx.doi.org/10.3389/fpubh.2023.1280658 |
work_keys_str_mv | AT leesarah publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx AT xiezidian publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx AT xuemily publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx AT shaoyihan publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx AT ossipdeborahj publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx AT lidongmei publicperceptionsofthefdasmarketingauthorizationofvuseontwitterx |